FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesShares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
to supply a new Bacillus Calmette-Guérin (BCG) source for bladder cancer treatment in the U.S. This development comes as a response to the shortage of TICE® BCG, which has affected patient treatment ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback